Minomic develops non-invasive blood tests for cancer. Its flagship product MiCheck uses a monclonal antibody to enable detection of a specific cancer-associated protein called Glypican-1. The company claims that the test is more sensitive and accurate than the gold standard prostate-specific antigen tests. The company was founded in 2000 and headquartered in Sydney, Australia. It has raised $8.1M in series a funding, with backing from ARC, NuSep, M.H. Carnegie & Co. The company operates in the Life Sciences - Oncology, Life Sciences - Genomics space. Non-invasive blood tests for cancer. Its offerings span Oncology - In-Vitro Diagnostic Tests - Prostate Cancer.
← All startups
Minomic
Series AMinomic develops non-invasive blood tests for cancer. Its flagship product MiCheck uses a monclonal antibody to enable detection of a specific cancer-associated protein called Glypican-1. The company claims that the test is more sensitive and accurate than the gold standard prostate-specific antigen tests. The company was founded in 2000 and headquartered in Sydney, Australia. It has raised $8.1M in series a…
About
Business model
Oncology > In-Vitro Diagnostic Tests > Prostate Cancer,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Liquid Biopsy
Institutional investors
ARCNuSepM.H. Carnegie & Co
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ Explore Life Sciences investors — funds that write checks in this sector.